You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石四藥集團(02005.HK):SYN045片50mg和100mg的單次給藥以及25mg的多次給藥臨牀試驗已經完成
格隆匯 07-07 12:04

格隆匯7月7日丨石四藥集團(02005.HK)公吿,近日,SYN045片50mg和100mg的單次給藥以及25mg的多次給藥臨牀試驗已經完成。研究結果顯示,人體藥代動力學特徵良好,安全性和耐受性較同靶點類藥物顯著提升,有利於實現口服長期給藥。截至目前,SYN045項目已提交發明專利合計18件,其中國際發明專利5件(已提交國際PCT申請);國內發明專利13件(當中化合物、晶型、製劑等相關5件發明專利已獲授權)。

視乎一期臨牀試驗的最終結果,集團正計劃開展二a期臨牀試驗,以確定人體內量效關係,並探索患者體內的有效性和安全性。

董事局亦欣然公吿以下集團其他新藥開發的最新情況:

1.抗癲癇創新藥集團自主研發的一項抗癲癇1類創新藥項目,靶點是鉀離子通道KCNQ2/3,目前正在開展化合物篩選,並準備進行毒性評估。2.疼痛類創新藥本集團自主研發的一項抗糖尿病周圍神經痛1類創新藥項目,靶點是銜接子相關蛋白激酶1(AAK1),目前正在開展化合物篩選。

3.改良新藥本集團目前正在開展三項新藥改良製劑的研究,其中兩項已經完成基於藥代動力學的處方研究,一項計劃今年內進行新藥臨牀試驗(IND)申報。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account